-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

905.O2.6 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Myeloma

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Adult, Biological, multiple myeloma, Diseases, CAR-Ts, Elderly, Therapies, Adverse Events, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Clinically relevant, Quality Improvement
Sunday, December 6, 2020: 12:00 PM-1:30 PM
Moderators:
Heather J Landau, MD, Memorial Sloan Kettering Cancer Center and Taiga Nishihori, MD, Moffitt Cancer Center
Disclosures:
Landau: Celgene/BMS: Other: Advisory Board; Pfizer: Honoraria, Other: Advisory Board; Janssen: Other: advisory Board; Caelum: Consultancy, Other: Advisory Board; Abbvie: Other: Advisory Board; Karyopharm: Consultancy, Other: Advisory Board; Takeda: Honoraria, Other: Advisory Board, Research Funding; Sanofi: Honoraria, Other: Advisory Board. Nishihori: Karyopharm: Other: Research support to institution; Novartis: Other: Research support to institution.
12:00 PM
436
Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients

Neha Korde, MD1, Elizabet Tavitian, BS1*, Andriy Derkach, PhD2*, Andrew Zarski3*, Meghan Salcedo, BSN, RN4*, Sham Mailankody, MBBS1, Hani Hassoun, MD1, Alexander M. Lesokhin, MD4, Nikoletta Lendvai, MD PhD5, Eric L Smith, MD, PhD6, Malin Hultcrantz, MD, PhD1, Sydney X. Lu, MD, PhD1, Carlyn Tan, MD7, Urvi A Shah, MD8, Benjamin Diamond, MD9, Dhwani Patel, MD1*, Gunjan L. Shah, MD MS10, Sergio A. Giralt, MD11, Sean Devlin, PhD12*, Thomas Atkinson13*, Joseph Lengfellner13* and Ola Landgren, MD, PhD1

1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
3Research and technology Management, Memorial Sloan Kettering Cancer Center, New York
4Memorial Sloan Kettering Cancer Center, New York, NY
5Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center/ Janssen Inc., New York, NY
6Dana Farber Cancer Institute, Boston
7Memorial Sloan Kettering Cancer Center, Philadelphia, PA
8Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
9MSKCC, NEW YORK, NY
10Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY
11Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
12Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
13Memorial Sloan Kettering Cancer Center, New York
12:15 PM
437
Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical TrialClinically Relevant Abstract

Nina Shah, MD1, Michel Delforge, MD PhD2, Jesús F. San-Miguel3, Kaitlyn B. Bertin4*, Muna J Tahir4*, Hannah B. Lewis5*, Julie Wang, PharmD, PhD6*, Julia Braverman, PhD6*, Timothy B. Campbell, MD, PhD6*, Devender Dhanda6* and Nikhil C. Munshi, MD7

1Associate Professor of Medicine, University of California San Francisco, San Francisco, CA
2Department of Hematology, University Hospital Leuven, Leuven, Belgium
3Clinical Universidad de Navarra, Pamplona, Spain
4ICON plc, South San Francisco, CA
5ICON plc, London, United Kingdom
6Bristol Myers Squibb, Princeton, NJ
7Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
12:30 PM
438
Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM scoreClinically Relevant Abstract

Rajshekhar Chakraborty, MD1*, Lisa Rybicki, MS2*, Jason Valent, MD3, Alex V. Mejia Garcia, MD4, Beth M. Faiman, PhD, CNP3, Jack Khouri, MD4, Nathaniel Rosko, PharmD5*, Christy J. Samaras, DO3, Matt Kalaycio, MD6, Faiz Anwer, MD4 and Alok A Khorana, MD5

1Department of Medicine, Columbia University Medical Center, New York
2Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
5Cleveland Clinic, Cleveland, OH
6Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH
12:45 PM
439
Symptom Burden in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Population-Based Study of Patient-Reported OutcomesClinically Relevant Abstract

Hira S Mian, MD1, Gregory R Pond, PhD, PStat1*, Branavan Sivapathasundaram, MSc2*, Tanya M. Wildes, MD, MSc3, Jonathan Sussman, MD, FRCPC, MSc4* and Hsien Seow, PhD4*

1Department of Oncology, McMaster University, Hamilton, ON, Canada
2McMaster University, Hamilton, ON, Canada
3Washington University, Saint Louis, MO
4Oncology, McMaster University, Hamilton, ON, Canada
1:00 PM
440
Effect of Geriatric Assessment and Intervention on Overall Survival Among Older Adults with Hematologic Malignancies

Sarah A Wall, MD1, Ying Huang, MS, MA2*, Nicholas Yuhasz3*, Colin Kloock4*, Edmund Folefac, MD5*, Carolyn Presley, MD5* and Ashley Rosko, MD1

1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
2Division of Hematology, The Ohio State University, Columbus, OH
3Comprehensive Cancer Center, The Ohio State University, Columbus, OH
4College of Medicine, The Ohio State University, Columbus, OH
5Division of Medical Oncology, The Ohio State University, Columbus, OH
1:15 PM
441
Baseline Patient-Reported Outcomes and Their Association with Hematopoietic Stem Cell Transplant Outcomes

Patrick Connor Johnson, MD1, Sunil M Bhatt, MD1*, Matthew J. Reynolds, BA1*, Zachariah Defilipp, MD2, Yi-Bin Chen, MD3 and Areej El-Jawahri, MD4

1Massachusetts General Hospital, Boston, MA
2Massachusetts General Hospital / Harvard Medical School, Boston, MA
3Blood and Marrow Transplant Program, Massachusetts General Hospital / Harvard Medical School, Boston, MA
4Massachusetts General Hospital / Harvard Medical School, Allston, MA
See more of: Oral and Poster Abstracts
<< Previous Session | Next Session >>
*signifies non-member of ASH